NEJM.org
@nejm.org
Welcome to the official Bluesky account for the New England Journal of Medicine. Follow for high-quality, peer-reviewed research and clinical content from the world’s leading medical journal, online at NEJM.org.
Follow @ai.nejm.org for medical AI content.
Follow @ai.nejm.org for medical AI content.
Pinned
Results from recently published, peer-reviewed studies support the safety and effectiveness of immunizations against Covid-19, RSV, and influenza. Learn more in a Special Article: nej.md/3L8m1gt
#MedSky #IDSky
#MedSky #IDSky
For a woman with symptomatic carotid-artery stenosis, would you recommend surgical carotid endarterectomy or percutaneous carotid-artery stenting? Read the case vignette, treatment options, and vote: nej.md/43fbIxg
#MedSky #MedEd
#MedSky #MedEd
November 10, 2025 at 8:08 PM
For a woman with symptomatic carotid-artery stenosis, would you recommend surgical carotid endarterectomy or percutaneous carotid-artery stenting? Read the case vignette, treatment options, and vote: nej.md/43fbIxg
#MedSky #MedEd
#MedSky #MedEd
A follow-up report showed that the overall benefit of machine perfusion over cold storage in kidney graft survival remained present 10 years after transplantation. Read the full report: nej.md/4hDQNK4
#MedSky #Nephrology #Surgery
#MedSky #Nephrology #Surgery
November 10, 2025 at 6:31 PM
A follow-up report showed that the overall benefit of machine perfusion over cold storage in kidney graft survival remained present 10 years after transplantation. Read the full report: nej.md/4hDQNK4
#MedSky #Nephrology #Surgery
#MedSky #Nephrology #Surgery
For moderate-to-severe plaque psoriasis, biologic therapies are highly effective but are available only by injection, and current oral therapies are often less effective. Research findings from the ATTAIN-1 phase 3 trial are summarized in a new Quick Take video. nej.md/47Upat0
#MedSky #EndoSky
#MedSky #EndoSky
November 10, 2025 at 5:02 PM
For moderate-to-severe plaque psoriasis, biologic therapies are highly effective but are available only by injection, and current oral therapies are often less effective. Research findings from the ATTAIN-1 phase 3 trial are summarized in a new Quick Take video. nej.md/47Upat0
#MedSky #EndoSky
#MedSky #EndoSky
In moderate-to-severe plaque psoriasis, oral icotrokinra led to a skin-clearance response in 50%–65% of patients at week 16, as compared with 4%–8% with placebo. The incidence of adverse events was similar in the two groups. Full ICONIC-LEAD trial results & Research Summary: nej.md/3WDM6qg
November 10, 2025 at 2:49 PM
In moderate-to-severe plaque psoriasis, oral icotrokinra led to a skin-clearance response in 50%–65% of patients at week 16, as compared with 4%–8% with placebo. The incidence of adverse events was similar in the two groups. Full ICONIC-LEAD trial results & Research Summary: nej.md/3WDM6qg
Tobevibart plus elebsiran and tobevibart alone both lowered HDV RNA and ALT levels. The combination resulted in a high incidence of undetectable HDV RNA and an HBsAg level below 10 IU/ml at week 48. Full SOLSTICE phase 2 trial results: nej.md/4qIXpuM
@aasldnews.bsky.social | #TLM25
@aasldnews.bsky.social | #TLM25
November 9, 2025 at 11:05 PM
Tobevibart plus elebsiran and tobevibart alone both lowered HDV RNA and ALT levels. The combination resulted in a high incidence of undetectable HDV RNA and an HBsAg level below 10 IU/ml at week 48. Full SOLSTICE phase 2 trial results: nej.md/4qIXpuM
@aasldnews.bsky.social | #TLM25
@aasldnews.bsky.social | #TLM25
A 1-week-old full-term baby boy was brought to the hospital for evaluation of discharge from his navel. A growth of pink tissue at the umbilicus that seeped yellow liquid was noted. Read the full case details: nej.md/4hLNwIQ
#MedSky #Neonatology @chugrenoblealpes.bsky.social
#MedSky #Neonatology @chugrenoblealpes.bsky.social
November 9, 2025 at 6:30 PM
A 1-week-old full-term baby boy was brought to the hospital for evaluation of discharge from his navel. A growth of pink tissue at the umbilicus that seeped yellow liquid was noted. Read the full case details: nej.md/4hLNwIQ
#MedSky #Neonatology @chugrenoblealpes.bsky.social
#MedSky #Neonatology @chugrenoblealpes.bsky.social
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo
#AHA25
#AHA25
November 9, 2025 at 4:14 PM
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo
#AHA25
#AHA25
A previously healthy 8-year-old boy was brought to clinic with a 7-day history of an itchy rash on his cheeks and a lacy rash on his chest and arms. He reported no recent fever, runny nose, or malaise. What is the most likely etiology of the rash? nej.md/IC11062025
November 9, 2025 at 3:22 PM
A previously healthy 8-year-old boy was brought to clinic with a 7-day history of an itchy rash on his cheeks and a lacy rash on his chest and arms. He reported no recent fever, runny nose, or malaise. What is the most likely etiology of the rash? nej.md/IC11062025
In patients with atrial fibrillation after successful ablation, rivaroxaban therapy did not lead to a significantly lower incidence of a composite of stroke, systemic embolism, or new covert embolic stroke than aspirin therapy. Full OCEAN trial results: nej.md/3LsRJ86
#AHA25
#AHA25
November 8, 2025 at 8:20 PM
In patients with atrial fibrillation after successful ablation, rivaroxaban therapy did not lead to a significantly lower incidence of a composite of stroke, systemic embolism, or new covert embolic stroke than aspirin therapy. Full OCEAN trial results: nej.md/3LsRJ86
#AHA25
#AHA25
ADAPT AF-DES trial: In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. nej.md/4nH8DgK
#AHA25
#AHA25
November 8, 2025 at 7:35 PM
ADAPT AF-DES trial: In patients with atrial fibrillation and a drug-eluting stent placed at least 1 year earlier, monotherapy with a non–vitamin K antagonist oral anticoagulant was noninferior to combination therapy with clopidogrel for net adverse clinical events. nej.md/4nH8DgK
#AHA25
#AHA25
In an interim analysis, sibeprenlimab, a humanized IgG2 monoclonal antibody that inhibits the proliferation-inducing ligand APRIL (a key driver of IgA nephropathy), reduced proteinuria as compared with placebo. nej.md/493Xtza
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
November 8, 2025 at 4:35 PM
In an interim analysis, sibeprenlimab, a humanized IgG2 monoclonal antibody that inhibits the proliferation-inducing ligand APRIL (a key driver of IgA nephropathy), reduced proteinuria as compared with placebo. nej.md/493Xtza
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
Among patients with atherosclerosis or diabetes but no previous myocardial infarction or stroke, evolocumab led to a lower risk of major adverse cardiovascular events than placebo. Full VESALIUS-CV trial results: nej.md/4oWrIN6
#AHA25
#AHA25
November 8, 2025 at 3:36 PM
Among patients with atherosclerosis or diabetes but no previous myocardial infarction or stroke, evolocumab led to a lower risk of major adverse cardiovascular events than placebo. Full VESALIUS-CV trial results: nej.md/4oWrIN6
#AHA25
#AHA25
Presented at #AHA25:
In a phase 1 trial, single-dose CRISPR-Cas9 gene editing targeting ANGPTL3 led to reductions in ANGPTL3 protein levels, with few adverse events. Full trial results: nej.md/43doGvu
In a phase 1 trial, single-dose CRISPR-Cas9 gene editing targeting ANGPTL3 led to reductions in ANGPTL3 protein levels, with few adverse events. Full trial results: nej.md/43doGvu
November 8, 2025 at 3:02 PM
Presented at #AHA25:
In a phase 1 trial, single-dose CRISPR-Cas9 gene editing targeting ANGPTL3 led to reductions in ANGPTL3 protein levels, with few adverse events. Full trial results: nej.md/43doGvu
In a phase 1 trial, single-dose CRISPR-Cas9 gene editing targeting ANGPTL3 led to reductions in ANGPTL3 protein levels, with few adverse events. Full trial results: nej.md/43doGvu
In the CORE-TIMI 72a and CORE2-TIMI 72b phase 3 trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. Full results: nej.md/491XG5V
#AHA25
#AHA25
November 8, 2025 at 2:45 PM
In the CORE-TIMI 72a and CORE2-TIMI 72b phase 3 trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. Full results: nej.md/491XG5V
#AHA25
#AHA25
In intermediate-risk breast cancer, postmastectomy chest-wall irradiation did not improve 10-year overall survival as compared with no chest-wall irradiation. Full SUPREMO phase 3 trial results and Research Summary: nej.md/3Jxd3sI
#MedSky #Oncology
#MedSky #Oncology
November 8, 2025 at 2:01 PM
In intermediate-risk breast cancer, postmastectomy chest-wall irradiation did not improve 10-year overall survival as compared with no chest-wall irradiation. Full SUPREMO phase 3 trial results and Research Summary: nej.md/3Jxd3sI
#MedSky #Oncology
#MedSky #Oncology
In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
November 7, 2025 at 4:36 PM
In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
For moderate-to-severe plaque psoriasis, biologic therapies are highly effective but are available only by injection, and current oral therapies are often less effective. Research findings from the ICONIC-LEAD phase 3 trial are summarized in a Quick Take video. nej.md/47o15uv
#MedSky #DermSky
#MedSky #DermSky
November 7, 2025 at 2:20 PM
For moderate-to-severe plaque psoriasis, biologic therapies are highly effective but are available only by injection, and current oral therapies are often less effective. Research findings from the ICONIC-LEAD phase 3 trial are summarized in a Quick Take video. nej.md/47o15uv
#MedSky #DermSky
#MedSky #DermSky
A 20-year-old man with Graves’ disease presented to the ED with a 2-hour history of confusion. A goiter, bounding carotid pulses, and bruits over the thyroid (shown in videos) were noted on physical examination. Read the full case details: nej.md/3XcXjy2
#MedSky #EndoSky
#MedSky #EndoSky
November 6, 2025 at 9:44 PM
A 20-year-old man with Graves’ disease presented to the ED with a 2-hour history of confusion. A goiter, bounding carotid pulses, and bruits over the thyroid (shown in videos) were noted on physical examination. Read the full case details: nej.md/3XcXjy2
#MedSky #EndoSky
#MedSky #EndoSky
In the latest episode of the Not Otherwise Specified podcast, host Lisa Rosenbaum, MD, and her guests explore the fraught relationship between medical training and primary care — and why even trainees who once aspired to be PCPs are changing course midstream.
#MedSky
#MedSky
November 6, 2025 at 7:03 PM
In the latest episode of the Not Otherwise Specified podcast, host Lisa Rosenbaum, MD, and her guests explore the fraught relationship between medical training and primary care — and why even trainees who once aspired to be PCPs are changing course midstream.
#MedSky
#MedSky
An 83-year-old man presented to the ED with generalized pruritus that had begun the previous night. One month earlier, he had been evaluated in the neurology department for a unilateral peripheral facial-nerve palsy. Read the full case details: nej.md/47pvyIL
#MedSky #NeuroSky
#MedSky #NeuroSky
November 6, 2025 at 5:08 PM
An 83-year-old man presented to the ED with generalized pruritus that had begun the previous night. One month earlier, he had been evaluated in the neurology department for a unilateral peripheral facial-nerve palsy. Read the full case details: nej.md/47pvyIL
#MedSky #NeuroSky
#MedSky #NeuroSky
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. nej.md/3JEq8QL
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
November 6, 2025 at 2:55 PM
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. nej.md/3JEq8QL
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
New in the November 6, 2025, issue of NEJM:
Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI
Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg
#MedSky
Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI
Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg
#MedSky
November 6, 2025 at 2:03 PM
New in the November 6, 2025, issue of NEJM:
Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI
Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg
#MedSky
Survival after Chest-Wall Irradiation in Breast Cancer (SUPREMO phase 3 trial) nej.md/3Jxd3sI
Oral Icotrokinra for Plaque Psoriasis (ICONIC-LEAD phase 3 trial) nej.md/3WDM6qg
#MedSky
Opioid deprescribing is advised when risks of opioid use outweigh benefits. A tailored, patient-centered plan with gradual dose reduction, monitoring, and support can improve outcomes and reduce harm. Learn more: nej.md/4oL3fu2
#MedSky @sydney.edu.au
#MedSky @sydney.edu.au
November 5, 2025 at 11:01 PM
Opioid deprescribing is advised when risks of opioid use outweigh benefits. A tailored, patient-centered plan with gradual dose reduction, monitoring, and support can improve outcomes and reduce harm. Learn more: nej.md/4oL3fu2
#MedSky @sydney.edu.au
#MedSky @sydney.edu.au
In a phase 1 trial in the United States and Liberia, a replication-competent recombinant vesicular stomatitis virus–vectored vaccine against Lassa fever had acceptable safety and was immunogenic over a wide dose range. Full trial results: nej.md/47pstZ9
#MedSky #IDSky
#MedSky #IDSky
November 5, 2025 at 10:40 PM
In a phase 1 trial in the United States and Liberia, a replication-competent recombinant vesicular stomatitis virus–vectored vaccine against Lassa fever had acceptable safety and was immunogenic over a wide dose range. Full trial results: nej.md/47pstZ9
#MedSky #IDSky
#MedSky #IDSky